Aim To investigate the oral health of children and adolescents with type 1 diabetes (T1D) and its associations with diabetes‐related and lifestyle factors. Design Cross‐sectional study at a large tertiary hospital pediatric diabetes clinic. Oral examination determined dental caries experience and gingival health. Secondary outcome measures included salivary characteristics, oral hygiene and dietary practices, and diabetes‐related factors. Results Eighty children and adolescents with T1D participated; mean (SD) age and HbA1c were 13.4(2.6) years and 7.7(0.9)%, respectively. Forty‐seven (59%) participants had one or more decayed, missing or filled teeth; 75 (94%) participants had gingivitis. Half (50%) reported ≥3 hypoglycemic episodes necessitating rapid‐acting carbohydrate in the previous week. Sixty‐two participants (78%) had normal saliva flow, however, 42 (52%) had reduced salivary buffering capacity. Glycemic control (HbA1c) was not associated with caries experience, gingival health or salivary characteristics. Increased frequency of tooth brushing (OR, 0.11; 95%CI 0.01–0.97, p = 0.05) and interdental flossing (OR, 0.31; 95%CI 0.12–0.81, p = 0.02) were associated with lower caries experience. Interdental flossing (OR, 0.31; 95% CI 0.12–0.80, p = 0.02) and good oral hygiene (OR, 0.06; 95% CI 0.01–0.22, p < 0.001) were associated with less gingivitis. Conclusion Poor oral health is common in children with T1D, regardless of HbA1c. Given potential implications for short‐ and long‐term systemic health, this study demonstrates the need for targeted strategies to improve oral health in children with T1D.

Type 2 Diabetes mellitus is defined as metabolic disorder, for which the prevalence is getting very high close to a pandemic. Nearly more than three by fourth of the global population have type 2 Diabetes, making gestational diabetes and type 1 Diabetes (10%) with less incidence having symptoms like polydipsia, etc. It is diagnosed by Random, Post Prandial and Glycosylated Hemoglobin test. There are several class of medications like Alpha-Glycosidase Inhibitors, Biguanides & GLP-1 receptor agonists. Semaglutide is an agonist of glucagon-like-peptide 1 receptor. Formulation of Semaglutide into subcutaneous injection was successfully performed in the year of 2017 by Novo Nordisk, which was gloriously approved by the regulatory agencies. After two years from this incident, this drug was formulated and marketed in the form of tablet under the brand name "Rybellus". Semaglutide can also be considered as drug used in treatment of cardiovascular ailments like atherosclerosis other than anti-diabetic effect. Out of the oral GLP-1 agonizing agents, Semaglutide emerges to be one of the best drugs with anti-diabetic activity. The safety profile of oral Semaglutide is also looking greater in comparison with other members of the same class.